News

Exclusive to Roswell Park, ‘Armored CAR’ Clinical Trial Targets CD19+ Hematologic Malignancies

A phase 1 clinical trial underway exclusively at Roswell Park Comprehensive Cancer Center will evaluate a novel chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed or refractory hematologic malignancies whose tumor ...

News

Next Generation Armored Car T-Cell Therapy Trial Now Open

This Phase I/II trial will test the effectiveness, safety, side effects, and best dose of CD19-targeted Chimeric Antigen Receptor (CAR) modified T cells genetically engineered to secrete interleukin 12 (IL-12) in patients with hematologic B-cell malignancies.

News

Roswell Park Earns ‘Exceptional’ Rating from National Cancer Institute With Best-Ever Core Grant

Region’s only Comprehensive Cancer Center earns maximum rating, marking five decades of consecutive NCI support.

Video

First-in-Human Clinical Trial for B-cell Lymphoma Using “Armored” CAR T Cells Opens at Roswell Park

Chimeric antigen receptor (CAR) T-cell therapy is emerging as an effective therapeutic strategy for patients with B-cell lymphoid cancers.

Video

A Comprehensive Overview of Tumor-Infiltrating Lymphocyte (TIL) Therapy for Metastatic Melanoma

Tuesday, April 9, 2024 5:30 - 6:30 PM EDT - On the heels of the FDA’s recent approval of AMTAGVI (lifileucel) for unrescectable or metastatic melanoma, join Roswell Park subject matter experts for a comprehensive provider education event.

News

For Roswell Park’s Cell Therapy Team, Innovation is the Norm

Roswell Park Comprehensive Cancer Center is dedicated to becoming the leading cellular therapy innovation engine in the United States, if not the world, in the next 10 years.